obesity

Vivus’ Problems are Arena's Opportunities

Vivus’ Problems are Arena's Opportunities

Motley Fool

Are Arena and VIVUS Frenemies?

Are Arena and VIVUS Frenemies?

Motley Fool

A Realistic View Of Belviq In The Short Term

A Realistic View Of Belviq In The Short Term

Seeking Alpha

Does VIVUS Need a Partner?

Does VIVUS Need a Partner?

Motley Fool

What Orexigen Is Saying -- and Not Saying

What Orexigen Is Saying -- and Not Saying

Motley Fool

Down 20%: What Is VIVUS' Market Opportunity?

Down 20%: What Is VIVUS' Market Opportunity?

Motley Fool

Arena Pharmaceuticals' Solution to a Billion Dollar a Day Problem

Arena Pharmaceuticals' Solution to a Billion Dollar a Day Problem

Motley Fool

Arena Looks To Be The Clear Winner In The Weight Loss Space

Arena Looks To Be The Clear Winner In The Weight Loss Space

Seeking Alpha

Why Arena's Launch Will Be Strong, Despite Vivus' Weak Launch

Why Arena's Launch Will Be Strong, Despite Vivus' Weak Launch

Motley Fool

The Wild October Ride Of Vivus

The Wild October Ride Of Vivus

Seeking Alpha